Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2

Polina A. Egorova, Ilya B. Bezprozvanny

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


The effective therapeutic treatment and the disease-modifying therapy for spinocerebellar ataxia type 2 (SCA2) (a progressive hereditary disease caused by an expansion of polyglutamine in the ataxin-2 protein) is not available yet. At present, only symptomatic treatment and methods of palliative care are prescribed to the patients. Many attempts were made to study the physiological, molecular, and biochemical changes in SCA2 patients and in a variety of the model systems to find new therapeutic targets for SCA2 treatment. A better understanding of the uncovered molecular mechanisms of the disease allowed the scientific community to develop strategies of potential therapy and helped to create some promising therapeutic approaches for SCA2 treatment. Recent progress in this field will be discussed in this review article.

Original languageEnglish (US)
Pages (from-to)1050-1073
Number of pages24
Issue number4
StatePublished - Oct 1 2019


  • Spinocerebellar ataxia type 2
  • aggregation
  • calcium signaling
  • cerebellum
  • polyglutamine disorders

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2'. Together they form a unique fingerprint.

Cite this